Grade: research grade

Factory Location: hangzhou, China.

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Monthly Production Capacity: grams

Packaging Information: 10mg,50mg, 100mg,1g,10g, 50g

Delivery Lead Time: 1-2 weeks

Sample Provided: yes

Payment Terms: T/T

ATX-GD-59   

Synonyms:ATX-GD-59 peptide therapy

Catalog No.:GT-L002

Molecular Formula:C114H198N32O32

Molecular Weight:2529.26

Key Specification:

Appearance:  White powder
Purity (HPLC) ≥98.0%

Single impurity≤1.5%

Peptide content≥70.0%

Amino Acid Composition≤±10%

Package:

Vacuum-packed with aluminum foil bag or transparent bag. 10mg,50mg, 100mg,1g,10g, 50g per package with icebag. Or according to your request. 

Description:

ATX-GD-59, as a pharmaceutical peptide, is a peptide-based therapy (peptide therapy). The main biological mechanism is to imitate epitopes to inactivate leukocytes that attack the thyroid, and prevent anti-thyroid stimulating hormone receptor (TSHR) stimulating antibodies. The immunological basis that can target Graves' disease is expected to become the first modified and innovative therapy for Graves' disease in 60 years. Clinically, ATX-GD-59 has good safety and tolerability in the treatment of Graves' disease, and it can even have normal thyroid stimulating hormone receptor (TSHR) antibody levels.

Storage:Cool dry place( Store at -20°C, away from the light)

Remark:For Research Use Only. Not for human use.